FEB 27, 2019 8:00 AM PST

Prepare for success: GMP cell banks as part of a staged, standardized, platform-style cell production process

Speaker
  • CEO and Co-Founder of Pluristyx Inc.
    Biography
      Ben Fryer is the CEO and co-founder of Pluristyx Inc. providing GMP pre-expanded pluripotent stem cells, contract development services, and consultancy for groups and company developing cell and tissue therapies. Ben has almost 25 years of experience as a leader and scientist in large pharma, academia, and start-up companies developing combination products and cell therapies. He has worked to generate GMP/ clinical grade pluripotent stem cells from early banking through large scale expansion using scalable, closed-loop, suspension reactor processes to manufacture cell therapy treatments for diabetes and heart disease.

      Ben is an inventor on multiple issued patents and patent applications for BetaLogics/Janssen/ J&J, including a bioreactor based, stem cell suspension expansion and differentiation process and a product currently marketed by Thermo-Fisher(TM) as Nunclon-Vita.

      Ben earned his BA from Colorado College, his PhD from UPENN, and studied as a post-doctoral fellow in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania investigating the role of Hypoxia Inducible Factor in cancer and stem cell development.

    Abstract
    DATE:  February 27, 2019
    TIME:  8:00am PST
     
    Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture replacement organs and cellular therapies. Many groups have shown therapeutic proof-of-concept of PSC-derived cells or tissues in relevant animal models, but PSCs are still more of a promise than a reality because of manufacturing challenges.  The task of manufacturing a sufficient number of cells under Good Manufacturing Practices (GMP) to enable clinical trials and eventual commercialization is a substantial hurdle. Furthermore, all allogeneic therapies, including those derived from PSCs, must meet strict regulatory requirements. One such requirement is the need for extensive, costly characterization and safety testing of the parental cell line and the subsequent master and working cell banks (MCB/WCB). The time and expense required to complete this testing necessitates the MCB be of sufficient quality and size to meet not only the requirements of a Phase 1 regulatory filing (IND), but also for the lifetime of the product through late stage trials and commercialization. This presentation will focus on the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and manufacturing workflow, beginning with the starting cell source and MCB.  Generation of a high-quality MCB is especially crucial for PSC-derived therapies because the first and most critically important step in product manufacturing is procurement of GMP-compliant starting material that meet regulatory requirements. Consequently, using high-quality raw materials from suppliers experienced in supporting cell therapy development and GMP manufacturing increase the probability of success and reduce the risk of costly surprises that could spell clinical or financial failure for a promising cell therapy product.  
     
    Learning Objectives:
    • Understand how and why cell banking is used for cell therapy manufacturing
    • Understand how and why to incorporate quality reagents and raw materials early in the development process
     
    Watch our related webinars here:
     
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
     

    Show Resources
    You May Also Like
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more